Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor

Int J Oncol. 2008 Aug;33(2):317-23.


This study examined overexpression of the opioid growth factor receptor (OGFr) in pancreatic cancer cells and phenotypic changes in tumorigenicity. Tumors of MIA PaCa-2 cells transfected with OGFr cDNA (OGFr-1) had 3.3 times more OGFr than empty vector (EV) neoplasias, and 4.3 times more OGFr than tumors from wild-type (WT) mice. No differences in OGFr binding were detected between tumors of EV and WT animals. Tumor incidence in OGFr-1 animals was reduced by up to 50% from EV mice. Latency times for OGFr-1 tumor expression were increased 30%, tumor volume was decreased 70%, and DNA synthesis was reduced 24% relative to EV mice. Exogenous OGF reduced OGFr-1 tumor volume up to 55% compared to OGFr-1 mice given vehicle. These data support OGFr gene function as a regulator of cell proliferation that impacts on tumorigenic expression, and suggest that molecular and pharmacological manipulation of OGFr may prevent or delay human pancreatic cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • DNA Replication / physiology
  • Disease Progression
  • Gene Expression
  • Humans
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Nude
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / pathology*
  • Receptors, Opioid / genetics
  • Receptors, Opioid / metabolism*
  • Transfection


  • Receptors, Opioid
  • methionine-enkephalin receptor